46
Participants
Start Date
September 30, 2015
Primary Completion Date
June 10, 2019
Study Completion Date
June 10, 2019
Atezolizumab
Participants will receive atezolizumab as per the schedule described in individual cohort.
Azacitidine
Participants will receive azacitidine as per the schedule described in individual cohort.
Montefiore Einstein Cancer Center, The Bronx
Roswell Park Cancer Institute; Grace Cancer Drug Center, Buffalo
University of Virginia Health System; Hematology/Oncology Division, Charlottesville
Medical University of South Carolina; Hollings Cancer Center, Charleston
Sarah Cannon Research Institute, Nashville
Cleveland Clinic Foundation, Cleveland
University of Kansas Medical Center, Westwood
University of Colorado Hospital - Anschutz Cancer Pavilion, Aurora
City of Hope, Duarte
University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco
Stanford University, Palo Alto
Fred Hutchinson Cancer Research Center, Seattle
Dana Farber Cancer Institute, Boston
University of Nebraska Medical Center; UNMC Oncology/Hematology, Omaha
The University of Texas MD Anderson Cancer Center, Houston
Hoffmann-La Roche
INDUSTRY